Recombinant Human Serpin E1/PAI-1 Protein

重组人Serpin E1/PAI-1蛋白 | 重组人类 Serpin E1/PAI-1 蛋白

Endothelial plasminogen activator inhibitor | Nexin | PAI1 | PAI-1 | PAI1PAI-1 | PAISerpin E1 | PLANH1 | PLANH1plasminogen activator inhibitor 1 | serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1), member 1

rp181294-50μg

50μg

无动物源

≥95%(SDS-PAGE)

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI 1 is the principal inhibitor of urokinase type plasminogen activator (uPA) and tissue type PA. As important regulators of extracellular matrix remodeling, uPA and PAI 1 play a major role in many processes such as angiogenesis, tumor invasion, and obesity. For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer. The human PAI-1 is initially synthesized as 402 amino acid precursor with an N terminal signal peptide. PAI 1 may exist in one of two possible conformations, designated as active or latent. The purified rhPAI 1 is active against rhuPA. The heterogeneity at the N terminus of the purified rhPAI 1 has been observed before for both the recombinant and native proteins.

Immobilized Recombinant Human Serpin E1/PAI-1 Protein (rp181294) at 2.0 μg/mL can bind PAI1 Mouse mAb (Ab120074) with the EC50 of 75 ng/mL.

重组表达

44.1 kDa

C-His

48.3 kDa, under reducing condition; 48.9 kDa, under non-reducing condition

HEK293 Accession #: P05121 | HEK293

<1.0 EU/μg

人(Human)

1-402 aa

MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEPHHHHHHHHHH

Yes

Yes